SG149892A1 - Identification of novel ige epitopes - Google Patents

Identification of novel ige epitopes

Info

Publication number
SG149892A1
SG149892A1 SG200900706-3A SG2009007063A SG149892A1 SG 149892 A1 SG149892 A1 SG 149892A1 SG 2009007063 A SG2009007063 A SG 2009007063A SG 149892 A1 SG149892 A1 SG 149892A1
Authority
SG
Singapore
Prior art keywords
identification
ige epitopes
novel ige
novel
epitopes
Prior art date
Application number
SG200900706-3A
Inventor
Sanjaya Singh
Danyang Huang
Sek Chung Michael Fung
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/002892 external-priority patent/WO2004070010A2/en
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of SG149892A1 publication Critical patent/SG149892A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

IDENTIFICATION OF NOVEL IGE EPITOPES
SG200900706-3A 2004-02-02 2004-07-29 Identification of novel ige epitopes SG149892A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2004/002892 WO2004070010A2 (en) 2003-02-01 2004-02-02 A method for generating high affinity antibodies
PCT/US2004/002894 WO2004070011A2 (en) 2003-02-01 2004-02-02 HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES

Publications (1)

Publication Number Publication Date
SG149892A1 true SG149892A1 (en) 2009-02-27

Family

ID=34841291

Family Applications (2)

Application Number Title Priority Date Filing Date
SG200900706-3A SG149892A1 (en) 2004-02-02 2004-07-29 Identification of novel ige epitopes
SG2012057212A SG183683A1 (en) 2004-02-02 2004-07-29 Identification of novel ige epitopes

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012057212A SG183683A1 (en) 2004-02-02 2004-07-29 Identification of novel ige epitopes

Country Status (8)

Country Link
EP (1) EP1718669A4 (en)
JP (1) JP2008507474A (en)
KR (4) KR20070008578A (en)
CN (1) CN102702359A (en)
AU (2) AU2004315197B2 (en)
CA (1) CA2552999A1 (en)
SG (2) SG149892A1 (en)
WO (1) WO2005075504A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009545330A (en) * 2006-08-04 2009-12-24 ザ トラスティーズ オブ ザ ユニバーシティー オブ ぺンシルべニア Methods and compositions for treating IGE-dependent diseases
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
CN101687932A (en) * 2007-02-15 2010-03-31 阿斯利康(瑞典)有限公司 Binding members for ige molecules
AR065368A1 (en) 2007-02-15 2009-06-03 Astrazeneca Ab ANTIBODIES FOR IGE MOLECULES
EP2012122A1 (en) * 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
EP2234637A2 (en) * 2007-12-21 2010-10-06 GlaxoSmithKline Biologicals S.A. Vaccines for malaria
DK2376108T3 (en) 2008-12-09 2017-04-24 Pfizer Vaccines Llc IgE CH3 peptide vaccine
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
EP3565587A4 (en) * 2017-01-06 2020-12-16 The Regents of The University of California Therapeutic anti-ige antibodies and methods and compositions thereof
WO2019186369A1 (en) * 2018-03-26 2019-10-03 Novartis Ag Methods of treating chronic spontaneous urticaria using ligelizumab
KR20240021856A (en) 2021-06-14 2024-02-19 노파르티스 아게 Pharmaceutical formulations containing anti-IgE antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63225397A (en) * 1986-10-03 1988-09-20 Dainippon Pharmaceut Co Ltd Novel peptide having antiallergic action
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2219640T3 (en) * 1992-09-24 2004-12-01 Novartis Ag REFORMED MONOCLONAL ANTIBODIES AGAINST AN IMMUNOGLOBULINE ISOTOPE.
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
ES2234180T3 (en) * 1998-04-09 2005-06-16 Idexx Laboratories, Inc. SPECIFIC FIXING PROTEINS FOR THE TREATMENT OF CANINE ALLERGY.
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
GB9822763D0 (en) * 1998-10-20 1998-12-16 Univ Sheffield Immunoglobin variant
NZ513680A (en) * 1999-02-25 2001-09-28 Peptide Therapeutics Ltd Epitodes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of IgE, antagonists thereof, and their therapeutic uses
GB9913327D0 (en) * 1999-06-08 1999-08-11 Smithkline Beecham Biolog Vaccine
GB0020717D0 (en) * 2000-08-22 2000-10-11 Smithkline Beecham Biolog Novel compounds and process
US6887472B2 (en) * 2000-08-30 2005-05-03 Pfizer Inc. Anti-IgE vaccines
GB0026334D0 (en) * 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
JP2003047482A (en) * 2001-05-22 2003-02-18 Pfizer Prod Inc IgE VACCINE FREE FROM ANAPHYLAXIS-INDUCING PROPERTY
GB0209878D0 (en) * 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
EP2000481B1 (en) * 2003-02-01 2016-03-30 Tanox, Inc. High affinity anti-human IgE antibodies

Also Published As

Publication number Publication date
SG183683A1 (en) 2012-09-27
WO2005075504A1 (en) 2005-08-18
KR20070008578A (en) 2007-01-17
AU2004315197A1 (en) 2005-08-18
KR101581659B1 (en) 2015-12-31
EP1718669A1 (en) 2006-11-08
KR101562114B1 (en) 2015-11-20
KR20130088198A (en) 2013-08-07
KR20120056297A (en) 2012-06-01
KR101365375B1 (en) 2014-02-19
EP1718669A4 (en) 2007-10-10
CN102702359A (en) 2012-10-03
KR20140021058A (en) 2014-02-19
CA2552999A1 (en) 2005-08-18
AU2009202408A1 (en) 2009-07-09
AU2004315197B2 (en) 2009-06-04
JP2008507474A (en) 2008-03-13

Similar Documents

Publication Publication Date Title
IL176940A0 (en) IDENTIFICATION OF NOVEL IgE EPITOPES
IN2014CN03629A (en)
GB0412973D0 (en) Identification of antibody producing cells
SG145694A1 (en) Novel compounds
EP1756092A4 (en) Novel inhibitors of rho-kinases
SG149855A1 (en) N-channel transistor
HK1115590A1 (en) Triazolophthalazines
MX2007008137A (en) Triazolophthalazines.
PT1761520E (en) Kinase inhibitors
UY3493Q (en) SPONGE
IL179811A0 (en) Identification of tumors
ATE512141T1 (en) USE OF TETRAHYDROBENZOXAZINES AS ANTIOXIDANTS
EP1869192A4 (en) Framework-shuffling of antibodies
HK1202299A1 (en) Novel cancer-associated antigen
MX2007002277A (en) Methods for making retinoids and uses thereof.
SG149892A1 (en) Identification of novel ige epitopes
GB0426160D0 (en) Production of proteins
SG142306A1 (en) Methods for neuroprotection
IL183106A0 (en) Production of proteins
GB2420856B (en) Measurement of corrosivity
SG158857A1 (en) Preparation of ketone amides
GB2458395B (en) Identification of the channel frequency response using stepped frequencies
EP1827482A4 (en) Novel uses of egf
GB0511304D0 (en) Production of leather
GB0424519D0 (en) Identification of micro-organisms